
NRC Health: stock overview
Price
$26.56
November 13, 2026Market cap $564M
What Ploutos Investor adds for NRC Health
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
NRC Health had revenue of $144M over the last 12 months and net income of $6.1M, a net margin of 4.3%. Revenue grew by 0.6% a year on average over the last 5 years. At $26.56 the shares trade at a P/E of 91.9, against a median of 28.4 over the last 5 fiscal years. It has net debt of $99M. It pays a dividend yielding 2.41%.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $564M
- 21.22M shares
- P/E
- 91.9
- Today91.9Median28.4
- Revenue, 12 months
- $144M
- +0.6% a year over 5 years
- Net margin
- 4.3%
- 2025: 8.4%, above 80% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-3.8% a year over 2 years
Fiscal years in figures
NRC's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $423M
- $564M
- Enterprise value
- $663M
- P/E 3-year median: 17.0
- 91.9
- EV / EBIT
- 41.7
- EV / Revenue
- 4.6
- P/B 3-year median: 19.3
- –
- FCF yield 3-year median: 3.7%
- 3.3%
- Earnings yield 3-year median: 5.9%
- 1.1%
Profitability
- Operating margin
- 11.1%
- Net margin 3-year median: 17.3%
- 4.3%
- ROIC
- 10.4%
- ROIC, 5-year average
- 31.4%
- ROE
- 78.2%
Growth
- Revenue, yearly change
- -4.0%
- EPS, yearly change
- +4,707.7%
- FCF, yearly change
- -17.9%
- Revenue, average a year
- +0.6%
- EPS, average a year
- +103.0%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $3.6M
- Total debt
- $103M
- Net debt
- $99M
- Net debt / EBITDA
- 4.2x
- Interest cover
- 2.9x
- Current ratio
- 0.64
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield 3-year median: 2.8%
- 2.41%
- Buybacks
- 3.58%
- Total returned
- 5.99%
- Shares, yearly change
- -1.8%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 87).
Operating margin
16.4%
Above 85% of the 43 companies in its industry, and 77% of all.
Net margin
8.4%
Above 80% of the 42 companies in its industry, and 62% of all.
ROE
82.9%
Above 91% of the 39 companies in its industry, and 98% of all.
ROA
8.6%
Above 74% of the 41 companies in its industry, and 84% of all.
Revenue growth
-4.0%
Above 24% of the 40 companies in its industry, and 19% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- NRC HEALTH
- CIK
- 70487
- Exchange
- NASDAQ
- Industry (SIC)
- 8731 · Services-Commercial Physical & Biological Research
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 21.22M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with NRC
- JNJJohnson & Johnson+0,00%Compare with NRC
- ABBVAbbVie+0,00%Compare with NRC
- UNHUnitedHealth+0,00%Compare with NRC
- MRKMerck & Company+0,00%Compare with NRC
- AMGNAmgen+0,00%Compare with NRC
- TMOThermo Fisher Scientific+0,00%Compare with NRC
- ABTAbbott Laboratories+0,00%Compare with NRC
The full analysis
What do NRC Health's filings show?
These are NRC Health's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is NRC's market cap?
NRC Health's market cap is $564M, at a price of $26.56 on November 13, 2026 and 21.22M shares.
What is NRC's P/E?
NRC's P/E is 91.9, on earnings per share of $0.27 over the last 12 months. The median over the last 5 fiscal years was 28.4.
How much revenue does NRC have?
NRC Health had revenue of $144M over the last 12 months. Over the last 5 years it changed by +0.6% a year on average.
Does NRC pay a dividend?
Yes. NRC Health paid $0.64 per share over the last 12 months, a yield of 2.41% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From NRC Health's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.